Breaking News
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

Moderna ETFs to Shine Bright on Booster Update, New Study Data

By Zacks Investment ResearchStock MarketsAug 14, 2021 08:55AM ET
www.investing.com/analysis/moderna-etfs-to-shine-bright-on-booster-update-new-study-data-200598589
Moderna ETFs to Shine Bright on Booster Update, New Study Data
By Zacks Investment Research   |  Aug 14, 2021 08:55AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
PFE
+0.54%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MRNA
+2.99%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Investors have dual reasons to be upbeat about the Moderna (NASDAQ:MRNA) MRNA stock. To begin with, the FDA has finally given a nod to the COVID-19 vaccine booster shots of Pfizer PFE-BioNTech or Moderna for people with weak immune systems. The decision has come at a time when the United States is seeing a sharp rise in the new coronavirus cases, arising from the highly-contagious delta variant even among the fully-vaccinated people.

In this regard, FDA Commissioner Dr. Janet Woodcock has said that “Today’s action allows doctors to boost immunity in certain immunocompromised individuals who need extra protection from COVID-19,” per a CNBC article. Patients suffering from cancer, HIV or those who have had organ transplants are mostly found to be immunocompromised individuals. Data suggests that these people don’t produce an adequate immune response despite being fully-vaccinated, per a CNBC article.

Notably, for the third shots to be administered on an immediate basis, the Centers for Disease Control and Prevention’s nod will be needed. The vaccine advisory committee will hold a meeting on Aug 13 to consider whether to issue a recommendation for shots for immunocompromised Americans, per the verified sources.

It is worth pointing out here that Israel has informed about its plans to administer booster shots to the population above 60 years, per a CNBC article. According to the same article, France has already started providing third shots to cancer patients or patients with other immune impairments.

In another positive development, Moderna informed about recently published new data on the durability of its COVID-19 vaccine in generating neutralizing antibodies against variants of concern like Alpha, Beta, Gamma, Delta, Epsilon and Iota. According to the company, the manuscript was published in Science. The data shows that majority of people that received both the shots of the Moderna’s COVID-19 vaccine maintained both binding and functional antibodies against SARS-CoV-2 variants for six months after the second dose.

Moderna ETFs to Gain

Considering the important role played by the coronavirus vaccines in Moderna’s recent earnings results, the latest developments can be positive for the stock. Notably, Moderna delivered 302 million doses of mRNA-1273, including 199 million doses in the second quarter, across the globe during the first half of 2021. The company expects to manufacture 800 million to 1 billion doses in 2021. It also projects to produce between 2 billion and 3 billion doses in 2022.

Interestingly, Moderna reported revenues of $4.4 billion in the second quarter, up from $67 million in the year-ago quarter. The major increase in revenues was driven by sales of its coronavirus vaccine, which is now approved for temporary/emergency use in several countries. Moreover, grants from an agreement with Biomedical Advanced Research and Development Authority (“BARDA”) related to development of the COVID-19 vaccine also drove revenues.

Therefore, we discuss a few ETFs that provide exposure to Moderna:

ETFMG Treatments Testing and Advancements ETF GERM

This fund is designed to give direct exposure to biotech companies, directly engaged in the testing and treatment of infectious diseases. It holds 77 stocks in its basket, with Moderna occupying the top spot at 10.77% share. The fund has amassed $67.5 million in its asset base and charges 68 basis points (bps) in annual fees (read: Are COVID-Themed ETFs Back in Focus as Delta Variant Fears Rise?).

VanEck Vectors Biotech ETF BBH

The underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. It holds about 24 securities in its basket, with 9.85% exposure to Moderna. Its AUM is $619.3 million and it has an expense ratio of 0.35% (read: How Are Biotech ETFs Reacting to These Q2 Earnings Releases?).

iShares Biotechnology ETF IBB

This fund seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector. It holds about 270 securities in its basket, with 9.82% exposure to Moderna. IBB has AUM of $11.44 billion, with an expense ratio of 0.45% (read: ETF Investing Areas to Consider for August).

iShares Genomics Immunology and Healthcare ETF IDNA

The fund seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. It holds about 48 securities in its basket, with 6.88% exposure to Moderna. IDNA has AUM of $342.2 million, with an expense ratio of 0.47% (read: A Comprehensive Guide to Genomic ETFs).


Infrastructure Stock Boom to Sweep America

A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.

The only question is “Will you get into the right stocks early when their growth potential is greatest?”

Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.

Download FREE: How to Profit from Trillions on Spending for Infrastructure >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Pfizer Inc. (NYSE:PFE): Free Stock Analysis Report

Moderna, Inc. (MRNA): Free Stock Analysis Report

iShares Biotechnology ETF (IBB): ETF Research Reports

VanEck Vectors Biotech ETF (BBH): ETF Research Reports

iShares Genomics Immunology and Healthcare ETF (IDNA): ETF Research Reports

ETFMG Treatments, Testing and Advancements ETF (GERM): ETF Research Reports

To read this article on Zacks.com click here.

Zacks Investment Research
Moderna ETFs to Shine Bright on Booster Update, New Study Data
 

Related Articles

Vince Martin
Micron Looks Like A Buy, But Not Yet By Vince Martin - Oct 04, 2022 3

So far, the market has shrugged off last week’s disappointing outlook from Micron The long view makes some sense, as Micron is an intensely cyclical company One key question:...

Mike Zaccardi, CFA, CMT
What Will the 'E' Be? By Mike Zaccardi, CFA, CMT - Oct 04, 2022 4

Investors are concerned about futures S&P 500 earnings A decent P/E valuation today might actually be quite pricey if estimates retreat Data show earnings recessions can last...

Moderna ETFs to Shine Bright on Booster Update, New Study Data

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email